Advances in antibody-drug conjugate in the treatment of urothelial carcinoma

Bai Xuesong; Yin Hubin; Kuang Youlin; Gou Xin

doi:10.13406/j.cnki.cyxb.003194

您当前的位置：

首页 >

文章列表页 >

Advances in antibody-drug conjugate in the treatment of urothelial carcinoma

Literature review | 更新时间：2025-10-21

- Advances in antibody-drug conjugate in the treatment of urothelial carcinoma
- Journal of Chongqing Medical University Vol. 48, Issue 3, Pages: 346-352(2023)
- 作者机构：
  
  重庆医科大学附属第一医院泌尿外科，重庆 400016
- 作者简介：
- 基金信息：
- DOI：10.13406/j.cnki.cyxb.003194
  CLC： R69
- Received：01 July 2022，
  
  Revised：2022-08-29，
  
  Accepted：20 September 2022，
  
  Published：28 March 2023
- 稿件说明：
移动端阅览
白雪松,印胡滨,匡幼林,等.抗体偶联药物治疗尿路上皮癌的研究进展[J].重庆医科大学学报,2023,48(3):346-352.

Bai Xuesong,Yin Hubin,Kuang Youlin,et al.Advances in antibody-drug conjugate in the treatment of urothelial carcinoma[J].Journal of Chongqing Medical University,2023,48(3):346-352.
白雪松,印胡滨,匡幼林,等.抗体偶联药物治疗尿路上皮癌的研究进展[J].重庆医科大学学报,2023,48(3):346-352. DOI： 10.13406/j.cnki.cyxb.003194.

Bai Xuesong,Yin Hubin,Kuang Youlin,et al.Advances in antibody-drug conjugate in the treatment of urothelial carcinoma[J].Journal of Chongqing Medical University,2023,48(3):346-352. DOI： 10.13406/j.cnki.cyxb.003194.

摘要

尿路上皮癌（urothelial carcinoma，UC）是泌尿系统常见的恶性肿瘤，在手术、化疗和免疫治疗等多种治疗措施下，仍有部分患者经历疾病复发、转移，预后不佳。抗体偶联药物（antibody-drug conjugate，ADC）兼有抗体药物的靶向性和化疗药物的细胞毒性，是近年来癌症个体化精准治疗的研究热点，成为这些患者新的选择。目前ADC治疗UC相关临床试验成果颇丰，靶向Nectin-4的Enfortomab Vedotin、靶向TROP-2的Sacituzumab Govitecan和靶向HER-2的Disitamab Vedotin已获批应用于临床，针对其他靶点的新型ADC也开始崭露头角。本文拟对最近的研究进展进行综述。

Abstract

Urothelial carcinoma（UC） is a common malignancy of the urological system. Under a variety of treatment measures，such as surgery，chemotherapy and immunotherapy，some patients still suffer disease recurrence and metastasis，leading to poor prognosis. Antibody-drug conjugate（ADC） combining the targeting of antibody drugs and the cytotoxicity of chemotherapeutic drugs，has recently become a research hotspot for individualized precision treatment of cancer and a new choice for these patients. At present，the clinical trials related to ADC in the treatment of UC have achieved fruitful results. Enfortomab Vedotin targeting Nectin-4，Sacituzumab Govitecan targeting TROP-2，and Disitamab Vedotin targeting HER-2 have been approved to be applied in clinical practice，and new ADCs for other targets have also begun to emerge. This article intends to review the latest research in this field.

关键词

Keywords

references

Sung H ， Ferlay J ， Siegel RL ， et al . Global cancer statistics 2020：GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries [J ] . CA Cancer J Clin ， 2021 ， 71 （ 3 ）： 209 - 249 .

Lenis AT ， Lec PM ， Chamie K ， et al . Bladder cancer：a review [J ] . JAMA ， 2020 ， 324 （ 19 ）： 1980 - 1991 .

Stecca C ， Abdeljalil O ， Sridhar SS . Metastatic urothelial cancer：a rapidly changing treatment landscape [J ] . Ther Adv Med Oncol ， 2021 ， 13 ： 175883592110473 .

Strebhardt K ， Ullrich A . Paul Ehrlich's magic bullet concept：100 years of progress [J ] . Nat Rev Cancer ， 2008 ， 8 （ 6 ）： 473 - 480 .

Khongorzul P ， Ling CJ ， Khan FU ， et al . Antibody-drug conjugates：a comprehensive review [J ] . Mol Cancer Res ， 2020 ， 18 （ 1 ）： 3 - 19 .

Zhao PX ， Zhang YB ， Li WQ ， et al . Recent advances of antibody drug conjugates for clinical applications [J ] . Acta Pharm Sin B ， 2020 ， 10 （ 9 ）： 1589 - 1600 .

Samanta D ， Almo SC . Nectin family of cell-adhesion molecules：structural and molecular aspects of function and specificity [J ] . Cell Mol Life Sci ， 2015 ， 72 （ 4 ）： 645 - 658 .

Hanna KS . Clinical overview of enfortumab vedotin in the management of locally advanced or metastatic urothelial carcinoma [J ] . Drugs ， 2020 ， 80 （ 1 ）： 1 - 7 .

FDA . FDA grants accelerated approval to enfortumab vedotin-ejfv for metastatic urothelial cancer [EB/OL ] . ( 2019-12-19 ) [ 2022-02-26 ] . https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-enfortumab-vedotin-ejfv-metastatic-urothelial-cancer https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-enfortumab-vedotin-ejfv-metastatic-urothelial-cancer .

Rosenberg JE ， O'Donnell PH ， Balar AV ， et al . Pivotal trial of enfortumab vedotin in urothelial carcinoma after platinum and anti-programmed death 1/programmed death ligand 1 therapy [J ] . J Clin Oncol ， 2019 ， 37 （ 29 ）： 2592 - 2600 .

Goldberg H . ESMO Virtual Congress 2020: Long-term results of enfortumab vedotin monotherapy for locally advanced or metastatic urothelial cancer in the EV-201 study in patients previously treated with platinum and PD-1/PD-L1 inhibitors [EB/OL ] . ( 2021-06-25 ) [ 2022-02-25 ] . https://www.urotoday.com/conference-highlights/esmo-2020/bladder- https://www.urotoday.com/conference-highlights/esmo-2020/bladder- cancer/124501-esmo-virtual-congress-2020-long-term-results-of-enfortumab-vedotin-monotherapy-for-locally-advanced-or-metastatic-urothelial-cancer-in-the-ev-201-study-in-patients-previously-treated-with-platinum-and-pd-1-pd-l1 -inhibitors .html.

Yu EY ， Petrylak DP ， O'Donnell PH ， et al . Enfortumab vedotin after PD-1 or PD-L1 inhibitors in cisplatin-ineligible patients with advanced urothelial carcinoma（EV‑201）：a multicentre，single-arm，phase 2 trial [J ] . Lancet Oncol ， 2021 ， 22 （ 6 ）： 872 - 882 .

Powles T ， Rosenberg JE ， Sonpavde GP ， et al . Enfortumab vedotin in previously treated advanced urothelial carcinoma [J ] . N Engl J Med ， 2021 ， 384 （ 12 ）： 1125 - 1135 .

SEAGEN . Seattle genetics and astellas announce updated results from phase 1b/2 Trial of PADCEV™ (enfortumab vedotin-ejfv) in combination with immune therapy pembrolizumab as investigational first-line treatment for advanced bladder cancer [EB/OL ] . ( 2020-02-11 ) [ 2022-02-26 ] . https://investor.seagen.com/press-releases/news-details/2020/Seattle-Genetics-and-Astellas-Announce-Updated-Results-from-Phase- https://investor.seagen.com/press-releases/news-details/2020/Seattle-Genetics-and-Astellas-Announce-Updated-Results-from-Phase- 1 b 2 -Trial-of-PADCEV-enfortumab-vedotin-ejfv-in-Combination-with-Immune-Therapy-Pembrolizumab-as-Investigational-First-Line- Treatment-for-Advanced-Bladder-Cancer/default .aspx.

ASTELLAS . Astellas and seattle genetics receive FDA breakthrough therapy designation for PADCEV™ (enfortumab vedotin-ejfv) in Combination with pembrolizumab in first-line advanced bladder cancer [EB/OL ] . ( 2020-02-19 ) [ 2022-02-26 ] . https://newsroom.astellas.us/2020-02-19-Astellas-and-Seattle-Genetics-Receive-FDA-Breakthrough- https://newsroom.astellas.us/2020-02-19-Astellas-and-Seattle-Genetics-Receive-FDA-Breakthrough- ough-Therapy-Designation-for-PADCEV-TM-enfortumab-vedotin-ejfv-in-Combination-with-Pembrolizumab-in-First-Line-Advanced-Bladder-Cancer.

Daniel PTW , Nataliya MAR . ASCO GU 2022: study EV-103 cohort H: antitumor activity of neoadjuvant treatment with enfortumab vedotin monotherapy in patients with MIBC who are cisplatin ineligible [EB/OL ] . ( 2022-01-19 ) [ 2022-03-16 ] . https://www.urotoday.com/conference-highlights/asco-gu-2022/asco-gu-2022-bladder-cancer/135463-asco-gu-2022-study-ev-103-cohort-h-antitumor-activity-of-neoadjuvant- treatment-with-enfortumab-vedotin-monotherapy-in-patients-with-mibc-who-are-cisplatin-ineligible.html https://www.urotoday.com/conference-highlights/asco-gu-2022/asco-gu-2022-bladder-cancer/135463-asco-gu-2022-study-ev-103-cohort-h-antitumor-activity-of-neoadjuvant-treatment-with-enfortumab-vedotin-monotherapy-in-patients-with-mibc-who-are-cisplatin-ineligible.html .

Gutierrez C ， Schiff R . HER2：biology，detection，and clinical implications [J ] . Arch Pathol Lab Med ， 2011 ， 135 （ 1 ）： 55 - 62 .

Zhao JJ ， Xu WD ， Zhang ZS ， et al . Prognostic role of HER2 expression in bladder cancer：a systematic review and Meta-analysis [J ] . Int Urol Nephrol ， 2015 ， 47 （ 1 ）： 87 - 94 .

中国抗癌协会肿瘤病理专业委员会，中国临床肿瘤学会尿路上皮癌专家委员会 . 中国尿路上皮癌人表皮生长因子受体2检测临床病理专家共识 [J ] . 中华肿瘤杂志， 2021 ， 43 （ 10 ）： 1001 - 1006 .

Tumor Pathology Committee of Chinese Anti-Cancer Association ， Expert Committee on Urothelial Carcinoma of Chinese Society of Clinical Oncology . Clinical pathological expert consensus on HER-2 testing in urothelial carcinoma in China [J ] . Chin J Oncol ， 2021 ， 43 （ 10 ）： 1001 - 1006 .

Peddi PF ， Hurvitz SA . Trastuzumab emtansine：the first targeted chemotherapy for treatment of breast cancer [J ] . Future Oncol ， 2013 ， 9 （ 3 ）： 319 - 326 .

von Minckwitz G ， Huang CS ， Mano MS ， et al . Trastuzumab emtansine for residual invasive HER2-positive breast cancer [J ] . N Engl J Med ， 2019 ， 380 （ 7 ）： 617 - 628 .

Li BT ， Makker V ， Buonocore DJ ， et al . A multi-histology basket trial of ado-trastuzumab emtansine in patients with HER2 amplified cancers [J ] . J Clin Oncol ， 2018 ， 36 （ 15_suppl ）： 2502 .

CLINICALTRIALS . GOV . A study to determine best tumor response with trastuzumab emtansine in human epidermal growth factor receptor 2 (HER2) overexpressing solid tumors (KAMELEON)[EB/OL ] . ( 2019-08-28 ) [ 2022-02-28 ] . https://clinicaltrials.gov/ct2/show/results/NCT02999672?term=NCT02999672&draw=2&rank=1 https://clinicaltrials.gov/ct2/show/results/NCT02999672?term=NCT02999672&draw=2&rank=1 .

Ogitani Y ， Aida T ， Hagihara K ， et al . DS-8201a，A novel HER2-targeting ADC with a novel DNA topoisomerase I inhibitor，demonstrates a promising antitumor efficacy with differentiation from T-DM1 [J ] . Clin Cancer Res ， 2016 ， 22 （ 20 ）： 5097 - 5108 .

Ogitani Y ， Hagihara K ， Oitate M ， et al . Bystander killing effect of DS-8201a，a novel anti-human epidermal growth factor receptor 2 antibody-drug conjugate，in tumors with human epidermal growth factor receptor 2 heterogeneity [J ] . Cancer Sci ， 2016 ， 107 （ 7 ）： 1039 - 1046 .

Modi SN ， Saura C ， Yamashita T ， et al . Trastuzumab deruxtecan in previously treated HER2-positive breast cancer [J ] . N Engl J Med ， 2020 ， 382 （ 7 ）： 610 - 621 .

Iwata TN ， Ishii C ， Ishida S ， et al . A HER2-targeting antibody-drug conjugate，trastuzumab deruxtecan （DS-8201a），enhances antitumor immunity in a mouse model [J ] . Mol Cancer Ther ， 2018 ， 17 （ 7 ）： 1494 - 1503 .

CLINICALTRIALS . GOV . Trastuzumab deruxtecan with nivolumab in advanced breast and urothelial cancer[EB/OL ] . ( 2021-08-12 ) [ 2022-04-12 ] . https://clinicaltrials.gov/ct2/show/NCT03523572?term=NCT03523572&draw=1&rank=1 https://clinicaltrials.gov/ct2/show/NCT03523572?term=NCT03523572&draw=1&rank=1 .

Xu YY ， Wang YK ， Gong JF ， et al . Phase I study of the recombinant humanized anti-HER2 monoclonal antibody-MMAE conjugate RC48-ADC in patients with HER2-positive advanced solid tumors [J ] . Gastric Cancer ， 2021 ， 24 （ 4 ）： 913 - 925 .

Sheng XN ， Yan XQ ， Wang L ， et al . Open-label，multicenter，phase II study of RC48-ADC，a HER2-targeting antibody-drug conjugate，in patients with locally advanced or metastatic urothelial carcinoma [J ] . Clin Cancer Res ， 2021 ， 27 （ 1 ）： 43 - 51 .

Cubas R ， Zhang S ， Li M ， et al . Trop2 expression contributes to tumor pathogenesis by activating the ERK MAPK pathway [J ] . Mol Cancer ， 2010 ， 9 ： 253 .

Syed YY . Sacituzumab govitecan：first approval [J ] . Drugs ， 2020 ， 80 （ 10 ）： 1019 - 1025 .

Pommier Y . Topoisomerase I inhibitors：camptothecins and beyond [J ] . Nat Rev Cancer ， 2006 ， 6 （ 10 ）： 789 - 802 .

FDA . FDA grants accelerated approval to sacituzumab govitecan for advanced urothelial cancer [EB/OL ] . ( 2021-04-13 ) [ 2022-02-26 ] . https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-sacituzumab-govitecan-advanced-urothelial-cancer https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-sacituzumab-govitecan-advanced-urothelial-cancer .

Tagawa ST ， Balar AV ， Petrylak DP ， et al . TROPHY-U-01：a phase II open-label study of sacituzumab govitecan in patients with metastatic urothelial carcinoma progressing after platinum-based chemotherapy and checkpoint inhibitors [J ] . J Clin Oncol ， 2021 ， 39 （ 22 ）： 2474 - 2485 .

Petros Grivas DP , Chandler H. PARK . ASCO GU 2022: TROPHY-U-01 Cohort 3: sacituzumab govitecan in combination with pembrolizumab in patients with metastatic urothelial cancer who progressed after platinum-based regimens [EB/OL ] . ( 2022-02-18 ) [ 2022-03-21 ] . https://www.urotoday.com/site-search.html?term=sacituzumab+govitecan+2022 https://www.urotoday.com/site-search.html?term=sacituzumab+govitecan+2022 & task=search.query & limitstart= 0 .

CLINICALTRIALS . GOV . Sacituzumab govitecan plus EV in metastatic UC[EB/OL ] . ( 2021-10-15 ) [ 2022-04-12 ] . https://clinicaltrials.gov/ct2/show/NCT04724018?term=NCT04724018&draw=2&rank=1 https://clinicaltrials.gov/ct2/show/NCT04724018?term=NCT04724018&draw=2&rank=1 .

Breij ECW ， de Goeij BECG ， Verploegen S ， et al . An antibody-drug conjugate that targets tissue factor exhibits potent therapeutic activity against a broad range of solid tumors [J ] . Cancer Res ， 2014 ， 74 （ 4 ）： 1214 - 1226 .

Markham A . Tisotumab vedotin：first approval [J ] . Drugs ， 2021 ， 81 （ 18 ）： 2141 - 2147 .

de Bono JS ， Concin N ， Hong DS ， et al . Tisotumab vedotin in patients with advanced or metastatic solid tumours（InnovaTV 201）：a first-in-human，multicentre，phase 1-2 trial [J ] . Lancet Oncol ， 2019 ， 20 （ 3 ）： 383 - 393 .

Eyvazi S ， Farajnia S ， Dastmalchi S ， et al . Antibody based EpCAM targeted therapy of cancer，review and update [J ] . Curr Cancer Drug Targets ， 2018 ， 18 （ 9 ）： 857 - 868 .

MacDonald GC ， Rasamoelisolo M ， Entwistle J ， et al . A phase I clinical study of VB4-845：weekly intratumoral administration of an anti-EpCAM recombinant fusion protein in patients with squamous cell carcinoma of the head and neck [J ] . Drug Des Devel Ther ， 2009 ， 2 ： 105 - 114 .

Kowalski M ， Entwistle J ， Cizeau J ， et al . A Phase I study of an intravesically administered immunotoxin targeting EpCAM for the treatment of nonmuscle-invasive bladder cancer in BCGrefractory and BCG-intolerant patients [J ] . Drug Des Devel Ther ， 2010 ， 4 ： 313 - 320 .

Kowalski M ， Guindon J ， Brazas L ， et al . A phase II study of oportuzumab monatox：an immunotoxin therapy for patients with noninvasive urothelial carcinoma in situ previously treated with Bacillus calmette-guérin [J ] . J Urol ， 2012 ， 188 （ 5 ）： 1712 - 1718 .

Dickstein R ， Wu N ， Cowan B ， et al . phase 3 trial of vicinium, an epcam-targeted pseudomonas exotoxin，in BCGunresponsive non-muscle invasive bladder cancer [EB/OL ] . ( 2018-03-20 ) [ 2022-03-16 ] . https://sesenbio.com/wp-content/uploads/2019/01/BLADDR_Congress_2018_Posterl.pdf https://sesenbio.com/wp-content/uploads/2019/01/BLADDR_Congress_2018_Posterl.pdf .

Deininger S ， Törzsök P ， Mitterberger M ， et al . From interferon to checkpoint inhibition therapy-a systematic review of new immune-modulating agents in Bacillus calmette-guérin（BCG） refractory non-muscle-invasive bladder cancer（NMIBC） [J ] . Cancers ， 2022 ， 14 （ 3 ）： 694 .

GERSHMAN J . FDA Denies vicineum approval for non-muscle invasive bladder cancer [EB/OL ] . ( 2021-09-01 ) [ 2022-04-12 ] . https://www.managedhealthcareexecutive.com/view/approval-of-vicineum-for-bladder-cancer-denied https://www.managedhealthcareexecutive.com/view/approval-of-vicineum-for-bladder-cancer-denied .

宋洪彬，刘冬连，李鹏飞，等 . 抗体偶联药物发展与进展 [J ] . 药学学报， 2019 ， 54 （ 10 ）： 1810 - 1817 .

Song HB ， Liu DL ， Li PF ， et al . Advanced research and technology development of antibody-drug conjugates [J ] . Acta Pharm Sin ， 2019 ， 54 （ 10 ）： 1810 - 1817 .

Views

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Comparison of the clinical efficacy of Disitamab Vedotin and postoperative chemotherapy in the treatment of HER-2 positive locally advanced urothelial carcinoma

Effect of miR-145 targeting ADAM17 on the growth of triple-negative breast cancer xenografts in nude mice and associated mechanism

Efficacy and safety of ADC combined with PD-1 inhibitors versus GC regimen in neoadjuvant therapy for bladder cancer

Predictive value of NLR and PLR for outcome after immunotherapy in advanced urothelial carcinoma

Advances in and reflections on bacteria-mediated oncology therapy

Related Author

Xu Qiao

Jiang Yu

Wan Shihao

He Yunfeng

Yan Li

Hu Baoshan

Shang Hongzhou

Zhang Xuepeng

Related Institution

School of Materials Science and Engineering，North China University of Science and Technology

Department of Surgical Oncology，The Affiliated Hospital of North China University of Science and Technology

Department of Urology,Chongqing University Fuling Hospital

Department of Urology,The Second Affiliated Hospital of Chongqing Medical University

Center for Intelligent Testing and Molecular Medicine， School of Medicine， Chongqing University

⁰